The EndoPredict second generation test gives clinicians individualized results for all eligible women with early-stage breast cancer to help them make confident treatment decisions about chemotherapy and long-term hormone therapy. Clinicians trust EndoPredict for its accurate prognostic and predictive performance.
EndoPredict is a CE-marked in vitro diagnostic (IVD) multiparameter gene expression test for breast cancer. It can be performed in local molecular pathology laboratories in many countries or ordered by clinicians from Myriad Genetics’ central laboratory in Salt Lake City, USA.
Results are available within a few days, allowing safe treatment decisions to be made quickly for the benefit of each woman with ER positive/HER2 negative early-stage breast cancer. The medium hands-on time takes just 2.5 hours, leading to a complete turnaround time of about 8 hours.
Our existing lab partners can upload their sample data and generate the EndoPredict result report here.
The EndoPredict gene expression test can be easily and accurately replicated, consistently delivering the same quality of results regardless of pathology lab.1
Test performance was evaluated in seven different molecular pathology labs across Germany, Austria and Switzerland:
EndoPredict is the most accurate prognostic test for breast cancer distant recurrence.2
The test has been developed and validated to include genes that predict both early and late metastasis.3-5 These improve prognostic power of EndoPredict compared with first generation tests, like Oncotype DX and MammaPrint. 2
Learn more about EndoPredict’s superior accuracy
Try it by generating an example test report below.
EndoPredict is available as a CE-marked IVD kit that can be run in local molecular pathology laboratories after a comprehensive onsite training, provided by Myriad Genetics.